Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria.
Sign Up to like & getrecommendations! Published in 2018 at "Allergy and asthma proceedings"
DOI: 10.2500/aap.2018.39.4136
Abstract: BACKGROUND Bilastine is an H1-antihistamine approved for symptomatic treatment of patients with allergic rhinoconjunctivitis or urticaria. The safety profile of bilastine in clinical trials of allergic rhinoconjunctivitis or urticaria, assessed by type and frequency of… read more here.
Keywords: safety profile; safety; bilastine; rhinoconjunctivitis urticaria ... See more keywords